TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Activities Scales for Kids
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Differentiation of causes of acute dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade improvement in submental fat assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who see a doctor because of high blood pressure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Left atrial minimum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of inhalation anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fresh gas flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaiser Physical Activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Symptom Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of the inspiratory open loop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first event of stent dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neuropathic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline body composition at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline inflammation at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline perceived quality of Life at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in ADOS-2 SA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of surgery at one-year after diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of smoking satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achievement of composite clinical/radiological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in retinal nerve fiber layer thickness (RNFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic performance of ultrasound elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MCAv
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Carnitine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Virtual Reality and 3D Reconstruction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Virtual Reality and 3D Reconstruction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: thickness of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: T-I differences for hyoid bone to skin distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-I differences for anterior commissure to skin distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-I differences for epiglottis to skin distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-I differences for thyroid isthmus to skin distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who can stand unassisted for at least 3 seconds at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment failure within 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant bone height changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that know first aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants that learnt first aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants that retain the first aid knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cellular mediators of thrombin generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of maximal voluntary isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Galvanic skin response (GSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NNAL Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve linear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patent intercostal and lumbar arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from Baseline Serum Albumin at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Serum Albumin at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Serum Albumin at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Self Compassion Scale (SCS) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve (AUC) of an abbreviated Snakebite Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete head-lift recovery defined by a 5-second head-lift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of enrollment of Underrepresented Populations (URPs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically relevant changes in safety parameters: systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of radiprodil and maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective radiographic response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial expressions during spontaneous breathing trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Parameter Monitoring Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of perioperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: traditional postpartum practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postpartum quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ureter conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients having conversations about SU use
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: AUC0-24 - Area Under the Concentration-time Curve From Time Zero to 24 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Network Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rhinoconjunctivitis Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in ctDNA with RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ctDNA with progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: curative-intent resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of laryngeal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrent progression of Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pressure injury knowledge level of students
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Students' pressure injury attitude level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with Vaccine Response or Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean intensity of chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fridericia-corrected QT interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in non-methadone opioid use (urine toxicology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in non-methadone opioid use (Timeline Follow Back)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular extracellular mass index (ECMi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of recent cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of tooth wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk level of tooth wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AMX0114
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of flavan-3-ols monomer (poly)phenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritable Bowel Syndrome Quality of Life (IBSQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clostridial changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Absolute Oral Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate unpleasantness of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating cell-free DNA of renal origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patient with adverse events / serious adverse events (AEs/SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicity (DLT) of KF-0210
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of KF-0210 alone
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the serum concentration versus time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-Related Adverse Events (TRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Potential Phase 2 dose (RP2D) to be further evaluated in Part 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of AEs, SAEs, AESIs including IARs
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormality in clinical laboratory, vital signs, and ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of the bowel cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Heart Rate Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial stay time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Placenta tissues and umbilical cord staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unpleasant psychotropic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Perception of the users of website content
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Website Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall impression
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coma Recovery Scale Revised (CRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary aeration of the ventilated lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Bispectral Index (BIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal layers and macular thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guideline-concordant antibiotic use for adult pharyngitis
Endpoint domain: Adverse events/effects
Primary endpoint: Guideline-concordant antibiotic use for pediatric acute otitis media
Endpoint domain: Adverse events/effects
Primary endpoint: Guideline-concordant antibiotic use for CAP
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in test values of Fundamental Motor Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days worked in past 30 days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Thromboxane A2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chest Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MMR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate of HIV-1-specific serum IgG binding antibodies against autologous and heterologous Env antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of HIV-1-specific serum IgG binding antibodies against autologous and heterologous Env antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of SAEs leading to early participant withdrawal or permanent discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pressure pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive psychological capital
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of immune cell types in mucosal sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ct value of viral genes in mucosal sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SARS-CoV-2, Influenza A and B-specific IgG titer in serum sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of All-Cause Revision
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Fragility Fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiota composition and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score in 28 joints (DAS-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entrapment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicidal and self-harm thoughts and behaviours
Endpoint domain: Adverse events/effects
Primary endpoint: Study questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of OCT biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of OCT biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the plasma concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of cytokines in peri-implant crevicular fluid associated with hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of cytokines in peri-implant crevicular fluid associated with bacterial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of Matrix Metalloproteinases in peri-implant crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of RANKL in peri-implant crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients that achieved haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients that show signs of life
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reporting at least a 50% reduction in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of MLE and DBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms and physical disability in KOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) in KOA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical efficacy of immunotherapy combined with chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Eligible Parents Screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Eligible Parents Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decision Aid Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Parents Retained in the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful Navigation to the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful tool-in-lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: electrolytes (Na, K, Cl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: liver condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amino acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LH/FSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 30 Second Sit to Stand Test (30SST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Stairs Climb Test (10SCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in supportive care needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Density of nasal mucosal bacterial colonization (CFU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of sIgA antibodies (ng/mL) against the vaccine strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abundance of nasal mucosal bacterial colonization (α Diversity and β Diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects in remission at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean VITA Shade Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratumoral T-cell infiltration of CD8+C45RO+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of relevant (S)AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change of in-brace scoliosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalised Joint Hypermobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes